$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc

$imuc Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000082241118000004 Filed on March 14, 2018

Income Statement

Concept	2018 Q1	2017 Q4	2017
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$734.6K	$1.108M	$4.027M
YoY Change	-7.02%	-43.16%	-19.56%
% of Gross Profit
Research & Development	$290.6K	-$676.7K	$17.13M
YoY Change	-93.8%	-112.6%	-10.36%
% of Gross Profit
Depreciation & Amortization	$106.00	$640.00	$47.77K
YoY Change	-99.36%	-96.8%	-36.41%
% of Gross Profit
Operating Expenses	$1.025M	$431.7K	$21.15M
YoY Change	-81.29%	-94.1%	-12.27%
Operating Profit	-$1.025M		-$21.15M
YoY Change	-81.29%		-12.27%
Interest Expense	$0.00	$400.00	$882.7K
YoY Change	-100.0%	-99.96%	-32.71%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.025M	-$431.3K	-$14.31M
YoY Change	-82.71%	-93.18%	-35.2%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.025M	-$431.3K	-$14.31M
YoY Change	-82.71%	-93.18%	-35.2%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$244.5K	-$123.1K	-$9.936M
COMMON SHARES
Basic Shares Outstanding	41.93M shares	35.20M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2017 Q4	2017
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.027M	$6.630M	$6.630M
YoY Change	-5.87%	-42.05%	-42.03%
Cash & Equivalents	$5.027M	$6.630M	$6.630M
Short-Term Investments
Other Short-Term Assets	$137.6K	$378.8K	$378.8K
YoY Change	-72.15%	-52.14%	-80.85%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$5.164M	$7.009M	$7.009M
YoY Change	-27.65%	-47.75%	-47.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$462.00	$568.00	$570.00
YoY Change	-99.5%	-99.48%	-99.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Assets	$462.00	$568.00	$570.00
YoY Change	-99.99%	-99.98%	-99.98%
TOTAL ASSETS
Total Short-Term Assets	$5.164M	$7.009M	$7.009M
Total Long-Term Assets	$462.00	$568.00	$570.00
Total Assets	$5.165M	$7.009M	$7.009M
YoY Change	-50.84%	-58.5%	-58.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.125M	$1.775M	$1.775M
YoY Change	22.99%	32.22%	32.22%
Accrued Expenses	$215.0K	$295.6K	$586.1K
YoY Change	-78.72%	-62.44%	-69.1%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.493M	$2.361M	$2.361M
YoY Change	-30.83%	-27.11%	-27.11%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.493M	$2.361M	$2.361M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.493M	$2.361M	$2.361M
YoY Change	-85.11%	-78.06%	-78.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$117.5M	-$116.4M
YoY Change	15.11%	21.01%
Common Stock	$121.1M	$121.1M
YoY Change	18.15%	18.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.672M	$4.648M	$4.648M
YoY Change
Total Liabilities & Shareholders Equity	$5.165M	$7.009M	$7.009M
YoY Change	-50.84%	-58.5%	-58.5%

Cashflow Statement

Concept	2018 Q1	2017 Q4	2017
OPERATING ACTIVITIES
Net Income	-$1.025M	-$431.3K	-$14.31M
YoY Change	-82.71%	-93.18%	-35.2%
Depreciation, Depletion And Amortization	$106.00	$640.00	$47.77K
YoY Change	-99.36%	-96.8%	-36.41%
Cash From Operating Activities	-$1.603M	-$4.929M	-$16.67M
YoY Change	-73.59%	31.79%	-16.07%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$1.330K
YoY Change
Cash From Investing Activities		$0.00	$1.326K
YoY Change			-133.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	5.553M	$11.86M
YoY Change	-100.0%	-4727.87%	36.34%
NET CHANGE
Cash From Operating Activities	-$1.603M	-4.929M	-$16.67M
Cash From Investing Activities		0.000	$1.326K
Cash From Financing Activities	$0.00	5.553M	$11.86M
Net Change In Cash	-$1.603M	624.6K	-$4.807M
YoY Change	-73.7%	-116.18%	-56.95%
FREE CASH FLOW
Cash From Operating Activities	-$1.603M	-$4.929M	-$16.67M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$4.929M	-$16.67M
YoY Change		31.79%	-16.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0000822411
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41928356	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q2	dei	Entity Public Float EntityPublicFloat	3010000	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	ImmunoCellular Therapeutics, Ltd.
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Trading Symbol TradingSymbol	IMUC
CY2017	imuc	Adjustments To Additional Paid In Capital Accretion Of Conversion Feature Of Preferred Stock AdjustmentsToAdditionalPaidInCapitalAccretionOfConversionFeatureOfPreferredStock	2284396	USD
CY2017	imuc	Adjustments To Additional Paid In Capital Preferred Stock Dividends AdjustmentsToAdditionalPaidInCapitalPreferredStockDividends	10024	USD
CY2017	imuc	Adjustments To Additional Paid In Capital Preferred Stock With Conversion Feature AdjustmentsToAdditionalPaidInCapitalPreferredStockWithConversionFeature	2284396	USD
CY2017	imuc	Adjustments To Additional Paid In Capital Public Offering Accretion Of Issuance Discount AdjustmentsToAdditionalPaidInCapitalPublicOfferingAccretionOfIssuanceDiscount	1033602	USD
CY2017	imuc	Adjustments To Additional Paid In Capital Public Offering Issuance Discount AdjustmentsToAdditionalPaidInCapitalPublicOfferingIssuanceDiscount	1033602	USD
CY2017	imuc	Adjustments To Additional Paid In Capital Warrant Repricing Accretion Of Financing Charge AdjustmentsToAdditionalPaidInCapitalWarrantRepricingAccretionOfFinancingCharge	41756	USD
CY2017	imuc	Adjustments To Additional Paid In Capital Warrant Repricing Financing Charge AdjustmentsToAdditionalPaidInCapitalWarrantRepricingFinancingCharge	41756	USD
CY2017	imuc	Adjustments To Additional Paid In Capital Warrants Exercised AdjustmentsToAdditionalPaidInCapitalWarrantsExercised	7774125	USD
CY2015	imuc	Change In Fair Value Of Warrant Liability For Income Taxes ChangeInFairValueOfWarrantLiabilityForIncomeTaxes	-0.08
CY2016	imuc	Change In Fair Value Of Warrant Liability For Income Taxes ChangeInFairValueOfWarrantLiabilityForIncomeTaxes	-0.07
CY2017	imuc	Change In Fair Value Of Warrant Liability For Income Taxes ChangeInFairValueOfWarrantLiabilityForIncomeTaxes	0.00
CY2015	imuc	Charge To Financing Expense ChargeToFinancingExpense	88939	USD
CY2016	imuc	Charge To Financing Expense ChargeToFinancingExpense	498520	USD
CY2017	imuc	Charge To Financing Expense ChargeToFinancingExpense	0	USD
CY2015Q1	imuc	Common Stock And Warrants Issued For Cash Per Share CommonStockAndWarrantsIssuedForCashPerShare	24.00
CY2016Q1	imuc	Common Stock Shares Purchased Private Placement Warrant CommonStockSharesPurchasedPrivatePlacementWarrant	91670	shares
CY2016Q1	imuc	Common Stock Value Authorized To Issue CommonStockValueAuthorizedToIssue	15081494	USD
CY2017Q4	imuc	Common Stock Value Available For Sale Under Agreement CommonStockValueAvailableForSaleUnderAgreement	14300000	USD
CY2017Q3	imuc	Common Stock Warrants Exercise Price Investor Relations Agreement CommonStockWarrantsExercisePriceInvestorRelationsAgreement	34772
CY2015	imuc	Deemed Dividend From Warrant Repricing DeemedDividendFromWarrantRepricing	0	USD
CY2016	imuc	Deemed Dividend From Warrant Repricing DeemedDividendFromWarrantRepricing	0	USD
CY2017	imuc	Deemed Dividend From Warrant Repricing DeemedDividendFromWarrantRepricing	41756	USD
CY2015	imuc	Derivative Instruments Warrants Reclassified To Additional Paid In Capital DerivativeInstrumentsWarrantsReclassifiedToAdditionalPaidInCapital	0	USD
CY2016	imuc	Derivative Instruments Warrants Reclassified To Additional Paid In Capital DerivativeInstrumentsWarrantsReclassifiedToAdditionalPaidInCapital	0	USD
CY2017	imuc	Derivative Instruments Warrants Reclassified To Additional Paid In Capital DerivativeInstrumentsWarrantsReclassifiedToAdditionalPaidInCapital	573560	USD
CY2015	imuc	Effective Income Tax Rate Reconciliation Derecognition Of Carryforward Adjustment Percent EffectiveIncomeTaxRateReconciliationDerecognitionOfCarryforwardAdjustmentPercent	0.00
CY2016	imuc	Effective Income Tax Rate Reconciliation Derecognition Of Carryforward Adjustment Percent EffectiveIncomeTaxRateReconciliationDerecognitionOfCarryforwardAdjustmentPercent	0.00
CY2017	imuc	Effective Income Tax Rate Reconciliation Derecognition Of Carryforward Adjustment Percent EffectiveIncomeTaxRateReconciliationDerecognitionOfCarryforwardAdjustmentPercent	-1.92
CY2015	imuc	Increase Decreasein Deferred Financing Costs IncreaseDecreaseinDeferredFinancingCosts	15041	USD
CY2016	imuc	Increase Decreasein Deferred Financing Costs IncreaseDecreaseinDeferredFinancingCosts	44711	USD
CY2017	imuc	Increase Decreasein Deferred Financing Costs IncreaseDecreaseinDeferredFinancingCosts	0	USD
CY2015	imuc	Issuance Of Warrants And Effect Of Repricing IssuanceOfWarrantsAndEffectOfRepricing	4286314	USD
CY2016	imuc	Issuance Of Warrants And Effect Of Repricing IssuanceOfWarrantsAndEffectOfRepricing	2427183	USD
CY2017	imuc	Issuance Of Warrants And Effect Of Repricing IssuanceOfWarrantsAndEffectOfRepricing	0	USD
CY2015	imuc	Liability Reclassified To Other Current Assets LiabilityReclassifiedToOtherCurrentAssets	0	USD
CY2016	imuc	Liability Reclassified To Other Current Assets LiabilityReclassifiedToOtherCurrentAssets	0	USD
CY2017	imuc	Liability Reclassified To Other Current Assets LiabilityReclassifiedToOtherCurrentAssets	108984	USD
CY2015	imuc	Net Book Value Of Property Plant And Equipment Transferred As Settlement Of Accounts Payable NetBookValueOfPropertyPlantAndEquipmentTransferredAsSettlementOfAccountsPayable	0	USD
CY2016	imuc	Net Book Value Of Property Plant And Equipment Transferred As Settlement Of Accounts Payable NetBookValueOfPropertyPlantAndEquipmentTransferredAsSettlementOfAccountsPayable	0	USD
CY2017	imuc	Net Book Value Of Property Plant And Equipment Transferred As Settlement Of Accounts Payable NetBookValueOfPropertyPlantAndEquipmentTransferredAsSettlementOfAccountsPayable	58455	USD
CY2015	imuc	Non Cash Deferred Offering Costs NonCashDeferredOfferingCosts	0	USD
CY2016	imuc	Non Cash Deferred Offering Costs NonCashDeferredOfferingCosts	55505	USD
CY2017	imuc	Non Cash Deferred Offering Costs NonCashDeferredOfferingCosts	0	USD
CY2015	imuc	Preferred Stock Accretion Of Beneficial Conversion Feature PreferredStockAccretionOfBeneficialConversionFeature	0	USD
CY2016	imuc	Preferred Stock Accretion Of Beneficial Conversion Feature PreferredStockAccretionOfBeneficialConversionFeature	0	USD
CY2017	imuc	Preferred Stock Accretion Of Beneficial Conversion Feature PreferredStockAccretionOfBeneficialConversionFeature	2284396	USD
CY2015	imuc	Preferred Stock Accretion Of Issue Discount PreferredStockAccretionOfIssueDiscount	0	USD
CY2016	imuc	Preferred Stock Accretion Of Issue Discount PreferredStockAccretionOfIssueDiscount	0	USD
CY2017	imuc	Preferred Stock Accretion Of Issue Discount PreferredStockAccretionOfIssueDiscount	1033470	USD
CY2015	imuc	Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering	14599627	USD
CY2016	imuc	Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering	6345868	USD
CY2017	imuc	Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering	0	USD
CY2016	imuc	Public Offering Expenses PublicOfferingExpenses	1787787	USD
CY2015	imuc	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate	0
CY2015	imuc	Warrant Liability Gain Loss Included In Earnings WarrantLiabilityGainLossIncludedInEarnings	2925258	USD
CY2016	imuc	Warrant Liability Gain Loss Included In Earnings WarrantLiabilityGainLossIncludedInEarnings	3812398	USD
CY2017	imuc	Warrant Liability Gain Loss Included In Earnings WarrantLiabilityGainLossIncludedInEarnings	0	USD
CY2016	imuc	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate	0
CY2017	imuc	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate	0
CY2017Q3	imuc	Stock Issued During Period Shares Private Placement StockIssuedDuringPeriodSharesPrivatePlacement	20560	shares
CY2017	imuc	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	41000	USD
CY2016Q1	imuc	Stock Offering Maximum Public Float StockOfferingMaximumPublicFloat	75000000	USD
CY2015	imuc	Supplies Write Off SuppliesWriteOff	0	USD
CY2016	imuc	Supplies Write Off SuppliesWriteOff	0	USD
CY2017	imuc	Supplies Write Off SuppliesWriteOff	2349404	USD
CY2017	imuc	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Benefit TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxBenefit	1300000	USD
CY2017	imuc	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Provisional Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit	1300000	USD
CY2012Q1	imuc	Warrants Exercisable Period After Initial Issuance WarrantsExercisablePeriodAfterInitialIssuance	P5Y
CY2015	imuc	Warrants Exercised WarrantsExercised	0	USD
CY2016	imuc	Warrants Exercised WarrantsExercised	0	USD
CY2017	imuc	Warrants Exercised WarrantsExercised	0	USD
CY2015	imuc	Warrants Liability Transfers Net WarrantsLiabilityTransfersNet	0	USD
CY2016	imuc	Warrants Liability Transfers Net WarrantsLiabilityTransfersNet	0	USD
CY2017	imuc	Warrants Liability Transfers Net WarrantsLiabilityTransfersNet	0	USD
CY2017Q4	imuc	Working Capital WorkingCapital	4647903	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1342126	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1774626	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	786953	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	295612	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	266203	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16339	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	102354844	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121087939	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	551340	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	485524	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1871222	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1550739	shares
CY2016Q4	us-gaap	Assets Assets	16889990	USD
CY2017Q4	us-gaap	Assets Assets	7009225	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	13414789	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	7008657	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23222296	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22604481	USD
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	149000000	shares
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11437118	USD
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	249000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3444859	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41913256	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3444859	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41913256	shares
CY2017Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	2912629	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	344	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6629870	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-617815	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-11167363	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4807248	USD
CY2016Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	3462617	USD
CY2017Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	466875	USD
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	57.60
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	266831	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	4191	USD
CY2015	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2016	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2017	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	4098	USD
CY2017	us-gaap	Cumulative Effect On Retained Earnings Net Of Tax1 CumulativeEffectOnRetainedEarningsNetOfTax1	573560	USD
CY2016Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	100216	USD
CY2017Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	0	USD
CY2015Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	48977	USD
CY2015Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	2599308	USD
CY2016Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	3090903	USD
CY2017Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	2251184	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20091036	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27267545	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	851633	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22690344	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30358448	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3102817	USD
CY2016	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2016Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1955514	USD
CY2017Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	0	USD
CY2015	us-gaap	Depreciation Depreciation	36193	USD
CY2016	us-gaap	Depreciation Depreciation	75114	USD
CY2017	us-gaap	Depreciation Depreciation	47768	USD
CY2015	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	USD
CY2016	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	USD
CY2017	us-gaap	Dividends Preferred Stock DividendsPreferredStock	10024	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.87
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.89
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.23
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.32
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.35
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1.90
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.00
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.00
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.09
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.00
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.00
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.29
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.00
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.02
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.00
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0.00
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0.00
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0.00
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1109864	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	290516	USD
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y10M
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	194420	USD
CY2017	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2015	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	2925258	USD
CY2016	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	3812398	USD
CY2017	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
CY2015	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2016	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2017	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-1706	USD
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	7719440	USD
CY2016	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	-2220766	USD
CY2017	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	0	USD
CY2015	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	133905	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4616500	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5006398	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4027200	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12790814	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22085702	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14312007	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	805320	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	125363	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	490955	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	140943	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	788677	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1419673	USD
CY2015	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	3657913	USD
CY2016	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1311836	USD
CY2017	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	882683	USD
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-422448	USD
CY2016	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-5940	USD
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2368212	USD
CY2015	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	2209192	USD
CY2016	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	221545	USD
CY2017	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	-146430	USD
CY2015	us-gaap	Interest Expense InterestExpense	133905	USD
CY2016	us-gaap	Interest Expense InterestExpense	1311836	USD
CY2017	us-gaap	Interest Expense InterestExpense	882683	USD
CY2015	us-gaap	Interest Paid InterestPaid	0	USD
CY2016	us-gaap	Interest Paid InterestPaid	0	USD
CY2017	us-gaap	Interest Paid InterestPaid	0	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	19863	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	24381	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	4680	USD
CY2016Q4	us-gaap	Liabilities Liabilities	10758244	USD
CY2017Q4	us-gaap	Liabilities Liabilities	2360754	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16889990	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7009225	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3238943	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2360754	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	6945741	USD
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	0	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18591336	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8701094	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11863203	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-169750	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4015	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1326	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19039401	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19864442	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16671777	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-12790814	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-22085702	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-14312007	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12790814	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22085702	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17681653	USD
CY2017	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification	573560	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	15513091	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	24112125	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	21153444	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-15513091	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-24112125	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-21153444	USD
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3000000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	791485	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	378787	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	169750	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4015	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	1309648	USD
CY2017Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	4000000	USD
CY2016	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1500000	USD
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	4048078	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	14500000	USD
CY2015	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2016	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	691187	USD
CY2017	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2017	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2017	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1326	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6750	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	208750	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7815125	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	376026	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16907	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	109823	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	568	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10896591	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19105727	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17126244	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-96223442	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116443659	USD
CY2015	us-gaap	Revenues Revenues	0	USD
CY2016	us-gaap	Revenues Revenues	0	USD
CY2017	us-gaap	Revenues Revenues	0	USD
CY2016Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.00
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	916028	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	1228987	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	492185	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.934
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8220
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0180
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0131
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	9697	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	153776	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	71009	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	46075	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	48444	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.60
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.00
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	232869	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	267997	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	162665	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	91656	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	53.20
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	47.20
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	43.11
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	42.31
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	73448	shares
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.80
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	70.40
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	40.63
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	65.06
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	21.60
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.61
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.00
CY2016Q3	us-gaap	Share Price SharePrice	2.30
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y5M24D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M24D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M4D
CY2015Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	24.00
CY2016Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	6.40
CY2016	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	77141	shares
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1250	shares
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10296689	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3396522	USD
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	916028	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1228987	USD
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	492185	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6750	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	23291643	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	21720296	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	6131746	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	4648471	USD
CY2016Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.025
CY2016Q4	us-gaap	Supplies Supplies	1186186	USD
CY2017Q4	us-gaap	Supplies Supplies	0	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4197344	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7668104	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-27255631	USD
CY2015Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	4197375	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	597719	USD
CY2015Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1958775	USD
CY2016Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	573560	USD
CY2017Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2180092	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2798881	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14404344	shares
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font><font style="font-family:inherit;font-size:10pt;">—The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these consolidated financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0000822411-18-000004-index-headers.html	Edgar Link	pending
0000822411-18-000004-index.html	Edgar Link	pending
0000822411-18-000004.txt	Edgar Link	pending
0000822411-18-000004-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
imuc-123117x10k.htm	Edgar Link	pending
imuc-123117xexhibit1059.htm	Edgar Link	pending
imuc-123117xexhibit231.htm	Edgar Link	pending
imuc-123117xexhibit311.htm	Edgar Link	pending
imuc-123117xexhibit312.htm	Edgar Link	pending
imuc-123117xexhibit321.htm	Edgar Link	pending
imuc-123117xexhibit322.htm	Edgar Link	pending
imuc-20171231.xml	Edgar Link	completed
imuc-20171231.xsd	Edgar Link	pending
imuc-20171231_cal.xml	Edgar Link	unprocessable
imuc-20171231_def.xml	Edgar Link	unprocessable
imuc-20171231_lab.xml	Edgar Link	unprocessable
imuc-20171231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc

2018 Q1 Form 10-K Financial Statement

#000082241118000004 Filed on March 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMUC EOM Pharmaceutical Holdings, Inc. Stock $imuc

2018 Q1 Form 10-K Financial Statement

#000082241118000004 Filed on March 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc